RenovoRx

10/28/2025

Join us on Tuesday, November 4th at 5:00 PM PT for the TAMP (Trans-Arterial Micro-Perfusion) Peer-to-Peer Best Practices Workshop, and gain valuable insights into the TAMP therapy platform, enabled by the RenovoCath® device, designed for targeted locoregional therapeutic drug-delivery. Register here: https://bit.ly/49doAYj

10/27/2025

RenovoRx today announced that it will host its third quarter 2025 financial results and business highlights conference call on November 13, 2025, at 4:30 p.m. ET. On the call, RenovoRx’s management is expected to discuss the latest developments and achievements for its ongoing RenovoCath® device commercialization efforts, as well as for the Phase III TIGeR-PaC trial in locally advanced pancreatic cancer and the PanTheR Post-Marketing Registry Study. For more details, visit: https://bit.ly/42Uh4hm

10/23/2025

RenovoRx Chief Clinical Officer, Leesa Gentry, will be a speaker at taking place October 26th - 28th, 2025 in Atlanta, GA. The event brings together industry leaders to discuss innovations that are shaping the future of clinical research, learn more: https://bit.ly/4nmpwNN

10/21/2025

RenovoRx will host the TAMP (Trans-Arterial Micro-Perfusion) Peer-to-Peer Best Practices Workshop on Tuesday, November 4th at 5:00 PM PT, with cases presented by Dr. Ripal Gandhi and Dr. Juan Camacho Vasquez. This educational workshop is an interactive peer-to-peer forum designed for physicians to share their experiences, including case presentations, with the TAMP therapy platform, enabled by the RenovoCath® device. Register for the workshop here: https://bit.ly/49doAYj

10/17/2025

Dr. Ripal Gandhi, interventional radiologist at Miami Cancer Institute, will present during Session 5: "What’s New and Hot: Emerging Therapies and New Technologies" at tomorrow, October 18th. Dr. Gandhi will discuss the latest advances in oncology therapies and highlight RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) platform, designed for targeted drug-delivery via the RenovoCath® device, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. For event details: https://bit.ly/46KJ7Aj

10/10/2025

We are pleased to welcome internationally renowned interventional oncologist, Thierry de Baère, MD, PhD, to RenovoRx’s Scientific Advisory Board. Dr. de Baère is a leading expert on targeted drug-delivery and locoregional cancer therapies, learn more: https://bit.ly/4717k6c

10/09/2025

“Professor de Baère is an internationally recognized clinical expert and researcher who has made pioneering contributions to the field of interventional oncology, and we are honored to have him join our SAB,” said Ramtin Agah, MD, Chief Medical Officer and Founder of RenovoRx. https://bit.ly/4717k6c

10/09/2025

RenovoRx today announced the appointment of internationally renowned interventional oncologist Thierry de Baère, MD, PhD to RenovoRx’s Scientific Advisory Board (SAB). Professor de Baère is a leading expert on targeted drug-delivery and locoregional cancer therapies, and his expertise will further strengthen our SAB. Learn more: https://bit.ly/4717k6c

10/08/2025

The 20th Clinical Trials Strategic Summit kicks off today! RenovoRx Chief Clinical Officer, Leesa Gentry, will participate in a panel discussion tomorrow, October 9th at 12:45 p.m. PT. For event details: https://bit.ly/3VJVQP8

10/02/2025

Our CEO, Shaun Bagai, recently joined The Living Hope Podcast to discuss RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform designed for targeted drug-delivery via the RenovoCath® device, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Shaun also discussed advancements in the ongoing Phase III TIGeR-PaC clinical trial in . Listen here: https://bit.ly/4gSnwLh

10/01/2025

RenovoRx CEO, Shaun Bagai, spoke with PharmaShots. about recent corporate milestones. Milestones include expanding the Company’s IP portfolio, progress in commercialization efforts for RenovoCath® as a standalone targeted drug-delivery device, and advancements in the Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer and the PanTheR Post-Marketing Registry Study evaluating drug-delivery via RenovoCath to solid tumors. Read more:

Shots: RenovoRx, a clinical-stage life sciences company, is developing targeted oncology therapies and has created RenovoCath, an FDA-cleared novel drug delivery device. Its proprietary TAMP therapy platform enables precise delivery of therapeutics across the arterial wall near the tumor site, direc...

09/29/2025

RenovoRx Chief Clinical Officer, Leesa Gentry, will participate in a panel discussion focused on designing clinical trials optimized for performance at the 20th Clinical Trials Strategic Summit, taking place October 8th - 9th, 2025 in San Francisco, CA. For event details: https://bit.ly/3VJVQP8